KLOW Blend (BPC-157 + TB-500 + GHK-Cu + KPV) Blend Calculator

What's in This Blend

About This Blend

Does stacking four preclinical peptides in one vial actually make sense? The KLOW Blend (also called the KLOW Protocol) puts GHK-Cu (50mg), BPC-157 (10mg), TB-500 (10mg), and KPV (10mg) together in a fixed 5:1:1:1 ratio. It evolved from the three-peptide GLOW stack. The addition of KPV brought anti-inflammatory gut protection into the mix. Each component works through a separate mechanism. GHK-Cu is a copper-binding tripeptide first isolated by Loren Pickart in 1973. His gene expression studies (PMID 29986520) confirmed it modulates over 4,000 genes involved in collagen, elastin, and antioxidant enzyme production. BPC-157 is a 15-amino-acid gastric juice fragment. Predrag Sikiric's group in Zagreb has published over 100 preclinical papers showing it accelerates tendon outgrowth through FAK-paxillin signaling and protects gut mucosa (PMID 17713731). TB-500, a synthetic fragment of thymosin beta-4, promotes actin polymerization and cell migration. Goldstein's original work showed it increased keratinocyte migration 2- to 3-fold at concentrations as low as 10pg (PMID 10469335). KPV enters intestinal epithelial cells via the PepT1 transporter and suppresses NF-kB inflammatory signaling at nanomolar concentrations (Dalmasso et al., PMID 18061177). The typical community protocol runs 2000mcg total blend per day for 10 weeks, followed by 4 weeks off. Most of the interest comes from the GLP-1 companion use case. Users on semaglutide or tirzepatide report that KLOW reduces nausea and supports skin tightening during rapid weight loss. That framing is entirely anecdotal. No clinical endpoint data supports it. The FDA classified BPC-157 and GHK-Cu as Category 2 bulk drug substances in 2023-2024, restricting compounding pharmacy access. Both BPC-157 and TB-500 are WADA-prohibited. Research vendor pricing ranges from $65 to $170 per vial.